As the anticipation for ASH 2023 builds, Professor Graham Jackson, consultant haematologist and Myeloma UK’s Chief Clinical and Scientific Advisor, sheds light on the top abstracts to watch, offering a curated glimpse into the forefront of myeloma research.
The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…
The annual Scottish Cancer Conference was held in Glasgow on 18 November 2019. It was a unique gathering of organisations involved with cancer, including patients, pharmaceutical companies, clinicians and charities. It presented an opportunity to share, learn and network, as well as understand the latest developments in Scotland’s combined efforts to beat cancer. This year…
The 2nd Oxford Myeloma Workshop was a two-day event (1-2 August 2019) run by Oxford University Hospitals which focused on the current translational research priorities in myeloma. Patient Advocacy and Policy Research Officer, Dr Amy Capper was there to learn about the latest developments. Here are some of her highlights from the programme: Opening the…
The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…
OPTIMISING CURRENT TREATMENTS The number of drugs available as myeloma treatment has grown significantly over the last two decades with discovery and approval of immunomodulatory drugs (thalidomide, lenalidomide (Revlimid®) and pomalidomide (Imnovid®)), proteasome inhibitors (bortezomib (Velcade®), cafilzomib (Kyprolis®) and ixazomib (Ninlaro®)), histone deacetylase inhibitors (panobinostat) and monoclonal antibody drugs (daratumumab (Darzalex®) and elotuzumab (Empliciti®)). However,…
